Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.
Oncol Ther
; 10(1): 85-103, 2022 Jun.
Article
em En
| MEDLINE
| ID: mdl-35103936
ABSTRACT
Multiple myeloma (MM) remains incurable due to relapse, although the use of proteasome inhibitors, immunomodulatory drugs, CD38-targeting antibodies, and autologous stem cell transplantation (auto-SCT) significantly improve the clinical outcomes of patients with newly diagnosed MM. In recent years, the introduction of chimeric antigen receptor T-cell (CAR T-cell) therapy has brought hope to patients with refractory and relapsed MM. The graft-versus-myeloma effect of allogeneic SCT provides the possibility for curing a subset of MM patients. In this review, we summarize the recent advances and challenges of cellular immunotherapies for MM, focusing on auto-SCT, allogeneic SCT, and CAR T-cell approaches. We also discuss future directions, and propose a specific algorithm for cellular therapies for MM and probability of minimal residual disease-directed therapy.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncol Ther
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China